Rapid Micro Biosystems, Inc
Rapid Micro Biosystems is a U.S.-based life sciences technology company that develops the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing. Its system combines robotics, imaging, software, consumables, and services to replace manual microbiology testing workflows across global drug production facilities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutomated MQC instruments that replace manual microbial testing workflows in pharma plants.
Recurring proprietary test consumables used on installed Growth Direct systems.
LIMS connection software and Mold Alarm modules that extend system functionality.
Validation, installation, field service, and post-warranty service contracts.
Products
Reported · share of revenue- Products69.7 %
- Services30.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Customers are pharmaceutical manufacturers and CDMOs that need regulated microbial quality control for biologics, cell and gene therapies, vaccines, sterile injectables, and other healthcare products. The platform is used by large global sites that want to automate testing, improve data integrity, and standardize MQC workflows across multiple facilities.
Buy Growth Direct systems, consumables, and services to automate regulated MQC across large manufacturing networks.
Use the platform to support outsourced biologics and sterile manufacturing with standardized quality control.
Adopt the system for rapid microbial testing in advanced therapy production environments.
Purchase systems and consumables to speed release decisions and reduce manual lab work.
Strategy
The company is focused on expanding installed systems within existing customer networks and increasing utilization of consumables and software on each platform. It is also extending the Growth Direct platform with new applications, including rapid sterility, to broaden the addressable workflow and deepen customer adoption.
The business model depends on multi-site adoption and repeat system placements after initial validation.
Recurring pull-through improves revenue visibility as more systems enter routine use.
New applications can widen the addressable MQC workflow and increase system value.
Geography
Q1/2026The company sells globally through direct commercial and service teams in North America, Europe, and Asia-Pacific, supplemented by distributors in certain territories. Its installed base spans approximately 107 sites in 18 countries, with customers operating across multiple manufacturing locations.
Share of the revenue the company reports by geography.
Risks
The company depends on successful adoption of a specialized automation platform in highly regulated pharmaceutical workflows, so customer validation cycles, technical performance, and regulatory acceptance are central risks. It also faces concentration in a relatively small set of large customers, competition from established microbiology suppliers, and execution risk in scaling new products and manufacturing capacity.
- Dependence on customer validation and workflow adoptionImpact: HighLikelihood: High
Growth Direct must be validated inside regulated manufacturing processes before broad use.
Exposure: Pharmaceutical manufacturing customers
- Customer concentrationImpact: High
Sales are concentrated among a relatively small group of large global pharma accounts.
Exposure: Top pharmaceutical manufacturers and CDMOs
- Competition from traditional MQC suppliersImpact: MediumLikelihood: Medium
Established vendors can defend incumbent manual testing workflows and pricing.
Exposure: Microbiology testing and lab equipment market
- New product commercialization riskImpact: MediumLikelihood: Medium
Rapid Sterility and other new applications may face technical, manufacturing, or market adoption issues.
Exposure: New sterility-related applications
- Seasonality and timing variabilityImpact: MediumLikelihood: Low
Customer budget cycles and summer vacation periods can delay sales, deliveries, and onsite services.
Exposure: Quarterly revenue and service timing
Accounting
Judgemental itemsSystems, software, consumables, and services may be recognized at different points in time or over time.
Impact: Affects revenue timing and mix between recurring and non-recurring revenue
Customer budget cycles and summer shutdowns can delay orders, deliveries, and service work.
Impact: Creates uneven quarterly revenue and margin comparisons
Management must estimate assets, liabilities, and expenses using assumptions that may change as the business scales.
Impact: Can affect reported operating results and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Intelligent Bio Solutions Inc
INBS · Surgical & Medical Instruments & Apparatus
Greenland Mines Ltd
GRMLW · Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd is a U.S.-based development-stage life sciences company that has not yet generated operating revenue.
Microchip Technology Incorporated
MCHP · Semiconductors & Related Devices
Microchip Technology designs, manufactures, and sells embedded control solutions that help customers add intelligence, connectivity, and security to electronic products.
Standard BioTools Inc
LAB · Pharmaceutical Preparations
Mesa Laboratories, Inc
MLAB · Industrial Instruments For Measurement, Display, and Control
Mesa Laboratories designs and manufactures life sciences tools and critical quality control solutions used in regulated pharmaceutical, healthcare, and medical device applications.
Last updated: 24/09/2026